Yirong Jiang

Dongguan, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

Autologous transplant versus matched sibling donor transplant in intermediate-risk AML in CR1 with no detectable MRD: a biological assignment comparative study.

Autologous transplant versus matched sibling donor transplant in intermediate-risk AML in CR1 with no detectable MRD: a biological assignment comparative study.

Journal: Experimental hematology & oncology

Published: March 25, 2026

Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial.

Orelabrutinib versus chemoimmunotherapy in treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma: a randomized, phase 3 trial.

Journal: Signal transduction and targeted therapy

Published: December 23, 2025

Salvage therapy containing sorafenib and donor lymphocyte infusion is associated with improved outcomes for FLT3 wild-type acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation.

Salvage therapy containing sorafenib and donor lymphocyte infusion is associated with improved outcomes for FLT3 wild-type acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation.

Journal: Biomarker research

Published: June 24, 2025

Decitabine combined with reduced-intensity conditioning for older patients with acute myeloid leukemia in composite complete remission undergoing allogeneic hematopoietic stem cell transplantation: a multicenter, single-arm, phase 2 trial.

Decitabine combined with reduced-intensity conditioning for older patients with acute myeloid leukemia in composite complete remission undergoing allogeneic hematopoietic stem cell transplantation: a multicenter, single-arm, phase 2 trial.

Journal: The Lancet regional health. Western Pacific

Published: February 26, 2025

Clinical characteristics, treatment patterns, and survival outcomes of 1031 patients with peripheral T cell lymphoma in china: a multicenter, real-world study.

Clinical characteristics, treatment patterns, and survival outcomes of 1031 patients with peripheral T cell lymphoma in china: a multicenter, real-world study.

Journal: Discover oncology

Published: February 13, 2025

High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trial.

High-dose cytarabine with idarubicin consolidation for acute myeloid leukemia in first complete remission: a randomized controlled trial.

Journal: Leukemia

Published: January 20, 2025

Haploidentical peripheral blood stem cells combined with bone marrow or unrelated cord blood as grafts for haematological malignancies: an open-label, multicentre, randomised, phase 3 trial.

Haploidentical peripheral blood stem cells combined with bone marrow or unrelated cord blood as grafts for haematological malignancies: an open-label, multicentre, randomised, phase 3 trial.

Journal: The Lancet. Haematology

Published: September 19, 2024

Metagenomic Next-Generation Sequencing in the Diagnosis of Pulmonary Infections after Allogeneic Hematopoietic Stem Cell Transplantation.

Metagenomic Next-Generation Sequencing in the Diagnosis of Pulmonary Infections after Allogeneic Hematopoietic Stem Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: May 25, 2024

Phase I Clinical Trial of CD19 CAR-T Cells Expressing CXCR5 Protein for the Treatment of Relapsed or Refractory B-cell Lymphoma.

Phase I Clinical Trial of CD19 CAR-T Cells Expressing CXCR5 Protein for the Treatment of Relapsed or Refractory B-cell Lymphoma.

Journal: Current cancer drug targets

Published: February 09, 2024

18 months follow-up of deep molecular response 4.5 (MR4.5) with nilotinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a prospective, multi-center study in China.

18 months follow-up of deep molecular response 4.5 (MR4.5) with nilotinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia: a prospective, multi-center study in China.

Journal: Frontiers in medicine

Published: July 26, 2023

Evaluation of physician guideline adherence and areas for improvement in managing patients with chronic myeloid leukemia: a cross-sectional survey.

Evaluation of physician guideline adherence and areas for improvement in managing patients with chronic myeloid leukemia: a cross-sectional survey.

Journal: Leukemia & lymphoma

Published: June 07, 2023

Investigating the ibrutinib resistance mechanism of L528W mutation on Bruton's tyrosine kinase via molecular dynamics simulations.

Investigating the ibrutinib resistance mechanism of L528W mutation on Bruton's tyrosine kinase via molecular dynamics simulations.

Journal: Journal of molecular graphics & modelling

Published: April 16, 2023

Showing 1-12 of 19

Last Updated: 09/26/2026